Management of rheumatoid arthritis

  • T. D
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The management of rheumatoid arthritis (RA) has changed substantially over recent years. The emphases are now on early recognition of persistent synovitis in primary care, rapid referral to specialist services and prompt use of disease-modifying anti-rheumatic drugs (DMARDs). For patients with newly diagnosed active RA, a combination of DMARDs should be offered as first-line treatment as soon as possible. Corticosteroids should be administered in early disease, but are not a good long-term strategy for most patients. A multidisciplinary team is important, and patient education is essential. Tumour necrosis factor-alpha inhibitors and other cytokine modulators have had a big impact on the management of RA not responding to conventional DMARDs, but in the UK their use has been restricted by cost to patients who have failed on two DMARDs with ongoing active disease. It is sometimes possible to reduce therapy in patients who are doing well, but whether DMARDs can be safely stopped in all patients in remission is highly contentious. In future there may be improvements in early diagnosis and better prognostic markers, and health economic arguments may be able to extend the eligibility for biological drugs so that pharmacological strategies will make remission the rule and not the exception. © 2009 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • *rheumatoid arthritis/di [Diagnosis]
  • *rheumatoid arthritis/dm [Disease Management]
  • *rheumatoid arthritis/dt [Drug Therapy]
  • abatacept/dt [Drug Therapy]
  • abatacept/pe [Pharmacoeconomics]
  • adalimumab/dt [Drug Therapy]
  • adalimumab/sc [Subcutaneous Drug Administration]
  • alopecia/si [Side Effect]
  • aurothiomalate/ae [Adverse Drug Reaction]
  • aurothiomalate/dt [Drug Therapy]
  • aurothiomalate/im [Intramuscular Drug Administrati
  • azathioprine/ae [Adverse Drug Reaction]
  • azathioprine/dt [Drug Therapy]
  • combination chemotherapy
  • cornea disease/si [Side Effect]
  • corticosteroid/ae [Adverse Drug Reaction]
  • corticosteroid/ar [Intraarticular Drug Administrat
  • corticosteroid/do [Drug Dose]
  • corticosteroid/dt [Drug Therapy]
  • corticosteroid/im [Intramuscular Drug Administrati
  • corticosteroid/po [Oral Drug Administration]
  • cost effectiveness analysis
  • cyclosporin A/ae [Adverse Drug Reaction]
  • cyclosporin A/dt [Drug Therapy]
  • cyclosporin A/po [Oral Drug Administration]
  • demyelinating disease/si [Side Effect]
  • diarrhea/si [Side Effect]
  • disease activity
  • disease course
  • disease modifying antirheumatic drug/cb [Drug Comb
  • disease modifying antirheumatic drug/dt [Drug Ther
  • dose response
  • drug cost
  • drug efficacy
  • drug megadose
  • drug safety
  • drug tolerability
  • drug treatment failure
  • early diagnosis
  • etanercept/dt [Drug Therapy]
  • etanercept/sc [Subcutaneous Drug Administration]
  • folic acid/cb [Drug Combination]
  • glucocorticoid/cb [Drug Combination]
  • glucocorticoid/dt [Drug Therapy]
  • health care personnel management
  • heart failure/si [Side Effect]
  • human
  • hydroxychloroquine/ae [Adverse Drug Reaction]
  • hydroxychloroquine/dt [Drug Therapy]
  • hydroxychloroquine/po [Oral Drug Administration]
  • hypertension/si [Side Effect]
  • infection/si [Side Effect]
  • infliximab/dt [Drug Therapy]
  • infliximab/iv [Intravenous Drug Administration]
  • kidney disease/si [Side Effect]
  • leflunomide/ae [Adverse Drug Reaction]
  • leflunomide/dt [Drug Therapy]
  • liver function test
  • low drug dose
  • lung toxicity/si [Side Effect]
  • lupus like syndrome/si [Side Effect]
  • membranous glomerulonephritis/si [Side Effect]
  • methotrexate/ad [Drug Administration]
  • methotrexate/ae [Adverse Drug Reaction]
  • methotrexate/cb [Drug Combination]
  • methotrexate/dt [Drug Therapy]
  • methotrexate/pa [Parenteral Drug Administration]
  • methotrexate/po [Oral Drug Administration]
  • methotrexate/sc [Subcutaneous Drug Administration]
  • methylprednisolone/dt [Drug Therapy]
  • methylprednisolone/im [Intramuscular Drug Administ
  • monotherapy
  • mouth ulcer/si [Side Effect]
  • nausea/si [Side Effect]
  • neutropenia/si [Side Effect]
  • nonsteroid antiinflammatory agent/dt [Drug Therapy
  • osteoporosis/si [Side Effect]
  • patient care
  • patient education
  • priority journal
  • prognosis
  • proteinuria/si [Side Effect]
  • rash/si [Side Effect]
  • retinopathy/si [Side Effect]
  • review
  • rituximab/dt [Drug Therapy]
  • salazosulfapyridine/ae [Adverse Drug Reaction]
  • salazosulfapyridine/dt [Drug Therapy]
  • salazosulfapyridine/po [Oral Drug Administration]
  • side effect/si [Side Effect]
  • skin cancer/si [Side Effect]
  • thrombocytopenia/si [Side Effect]
  • time
  • tocilizumab/dt [Drug Therapy]
  • treatment response
  • triamcinolone acetonide/dt [Drug Therapy]
  • triamcinolone acetonide/im [Intramuscular Drug Adm
  • tumor necrosis factor alpha inhibitor/ae [Adverse
  • tumor necrosis factor alpha inhibitor/dt [Drug The
  • tumor necrosis factor alpha inhibitor/pe [Pharmaco

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Ding T.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free